Reports
Global Glaucoma Therapeutics Market Size, Growth, Analysis: By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Others; By Glaucoma Type; By Route of Administration; By Treatment Channel; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Glaucoma Therapeutics Market Outlook
The global glaucoma therapeutics market value in 2022 was USD 6.6 billion driven by the increasing technological advancements in glaucoma diagnosis and treatment across the globe. The market size is anticipated to grow at a CAGR of 5.2% during the forecast period of 2023-2031 to achieve a value of USD 10.5 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America to be Among the Significant Regional Markets for Glaucoma Therapeutics
North America is expected to be one of the leading regions in the glaucoma therapeutics market owing to high per capita expenditure on healthcare. Major players operating in the market have made a series of strategic acquisitions, contributing to their market share. Further, the increase in the geriatric population, rise in awareness about glaucoma, availability of reimbursements, and well-established health care infrastructure are the other factors driving the market growth in North America.
Europe and the Asia Pacific to Witness Significant Growth
The glaucoma therapeutics market in Europe is expected to increase due to favourable reimbursement policies during the forecast period. Factors contributing to the growth of the market in the region include stronger emphasis by federal governments on improving healthcare facilities and a rise in awareness among the population. On the other hand, the Asia Pacific would showcase the highest growth, fuelled by the increasing ageing population, especially in Japan and China, which require these therapeutics.
Market Segmentations
Various therapy options for primary open-angle (POA) and primary angle-closure (PAC) glaucoma are referred to as glaucoma therapeutics. The condition is marked by structural alterations in the optic nerves, resulting in vision loss and blindness. Topical eye drops, which include beta-blockers, prostaglandin analogues, cholinergic, carbonic anhydrase inhibitors, and alpha-adrenergic agonists, can treat glaucoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By drug class, the market includes:
- Prostaglandin Analogues
- Beta-Blockers
- Alpha Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Combination Drugs
- Others
Based on indication, the market is divided into:
- Open-Angle Glaucoma
- Angle Closure Glaucoma
- Others
The end-uses of the market are:
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgery Centres
- Others
The regional markets for the glaucoma therapeutics market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Prevalence of Glaucoma Propelling the Market Growth
One of the major factors driving the market's growth is the rising prevalence of glaucoma across the globe. Glaucoma is quite common among diabetic patients and people with additional visual problems, such as age-related macular degeneration (AMD), cataracts, and dry eye. Following this, the growing geriatric population, which is more vulnerable to such illnesses, propels the market growth. An increase in awareness of glaucoma, medical coverage of glaucoma patients and demand for combination glaucoma drugs are some of the significant trends that can be seen in the global glaucoma therapeutics industry. The industry is also being driven by rising health consciousness among the public and a growing preference for laser glaucoma surgery.
In addition, the invention of unique combination dugs is a growth-stimulating factor. Anti-glaucoma medicines and prostaglandin analogues are being developed by pharmaceutical companies in combination with two or more drugs to lower excessive IOP levels. Other factors, such as the introduction of better glaucoma diagnostic techniques and improvements in healthcare infrastructure, are expected to fuel the market growth further.
Key Players in the Global Market for Glaucoma Therapeutics
The report gives a detailed analysis of the following key players in the global glaucoma therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Aerie Pharmaceuticals Inc.
- Bausch & Lomb Incorporated
- Inotek Pharmaceuticals Corp.
- SIFI S.p.A
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Glaucoma Type |
|
| Breakup by Route of Administration |
|
| Breakup by Treatment Channel |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Glaucoma Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Glaucoma Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Glaucoma Epidemiology (2016-2031)
5.3 Europe Glaucoma Epidemiology (2016-2031)
5.4 Asia-Pacific Glaucoma Epidemiology (2016-2031)
5.5 Latin America Glaucoma Epidemiology (2016-2031)
5.6 Middle East & Africa Glaucoma Epidemiology (2016-2031)
6 Global Glaucoma Therapeutics Market Overview
6.1 Global Glaucoma Therapeutics Market Historical Value (2016-2022)
6.2 Global Glaucoma Therapeutics Market Forecast Value (2023-2031)
7 Global Glaucoma Therapeutics Market Landscape
7.1 Glaucoma Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Glaucoma Therapeutics: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Glaucoma Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by End User
7.2.5 Analysis by Distribution Channel
8 Glaucoma Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Glaucoma Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Glaucoma Therapeutics Market Segmentation
11.1 Global Glaucoma Therapeutics Market by Drug Class
11.1.1 Market Overview
11.1.2 Beta Blockers
11.1.3 Prostaglandins
11.1.4 Alpha Adrenergic Agonist
11.1.5 Carbonic Anhydrase Inhibitors
11.1.6 Combination Drugs
11.1.7 Others
11.2 Global Glaucoma Therapeutics Market by Glaucoma Type
11.2.1 Market Overview
11.2.2 Closed Angle Glaucoma (CAG)
11.2.3 Open Angle Glaucoma (OAG)
11.2.4 Secondary Glaucoma
11.2.5 Congenital Glaucoma
11.2.6 Others
11.3 Global Glaucoma Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parentals
11.3.4 Topicals
11.3.5 Others
11.4 Global Glaucoma Therapeutics Market by Treatment Channel
11.4.1 Market Overview
11.4.2 Public
11.4.3 Private
11.5 Global Glaucoma Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Homecare Settings
11.5.5 Others
11.6 Global Glaucoma Therapeutics Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Global Glaucoma Therapeutics Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Glaucoma Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Glaucoma Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Glaucoma Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Glaucoma Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Glaucoma Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Aerie Pharmaceuticals, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Allergan
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bausch Health
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Merck & Co. Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Pfizer Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Fera Pharmaceuticals
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Teva Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 EyePoint Pharmaceuticals
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Amorphex Therapeutics LLC.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Acorn Biomedical, Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Acucela Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Alcon
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Astellas Pharma Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Bayer AG
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 BioAxone
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Novartis AG
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Carl Zeiss Meditec
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Alcon, Lumenis
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Topcon Medical Systems
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Accutome
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
24 Glaucoma Therapeutics Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
Globally, glaucoma therapeutics market reached a value of USD 6.6 billion in 2022.
The market is projected to expand at a CAGR of 5.2% from 2022 to 2031, growing to USD 10.5 billion by 2031.
The major drivers of the market include favourable reimbursement policies, an increase in awareness of glaucoma, rising health consciousness, the invention of unique combination drugs, the introduction of better glaucoma diagnostic techniques and improvements in healthcare infrastructure.
The rising prevalence of glaucoma around the world and the growing geriatric population are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Based on drug class, the market includes prostaglandin analogues, beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and combination drugs, among others.
The various indications of the market are open-angle glaucoma and angle-closure glaucoma, among others.
The end-uses of the market are hospitals, ophthalmic clinics, and ambulatory surgery centres, among others.
The major players in the industry are Aerie Pharmaceuticals Inc., Bausch & Lomb Incorporated, Inotek Pharmaceuticals Corp., SIFI S.p.A, Viatris Inc., and Teva Pharmaceutical Industries Ltd., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER